GSK Plc (GSK)
50.46
-0.18
(-0.35%)
USD |
NYSE |
Nov 13, 16:00
50.46
0.00 (0.00%)
After-Hours: 18:10
GSK Net Income (Quarterly) : 2.289B for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.289B |
| June 30, 2026 | 742.26M |
| March 31, 2026 | 2.478B |
| December 31, 2025 | 966.83M |
| September 30, 2025 | 2.891B |
| June 30, 2025 | 2.197B |
| March 31, 2025 | 2.232B |
| December 31, 2024 | 642.07M |
| September 30, 2024 | 84.50M |
| June 30, 2024 | 1.645B |
| March 31, 2024 | 1.371B |
| December 31, 2023 | 493.76M |
| September 30, 2023 | 1.941B |
| June 30, 2023 | 2.184B |
| March 31, 2023 | 1.982B |
| December 31, 2022 | 1.906B |
| September 30, 2022 | 916.24M |
| June 30, 2022 | 935.73M |
| March 31, 2022 | 2.375B |
| December 31, 2021 | 566.05M |
| September 30, 2021 | 1.303B |
| June 30, 2021 | 1.777B |
| March 31, 2021 | 1.737B |
| December 31, 2020 | 1.108B |
| September 30, 2020 | 1.847B |
| Date | Value |
|---|---|
| June 30, 2020 | 3.029B |
| March 31, 2020 | 2.145B |
| December 31, 2019 | 1.952B |
| September 30, 2019 | 2.115B |
| June 30, 2019 | 1.350B |
| March 31, 2019 | 1.283B |
| December 31, 2018 | 1.672B |
| September 30, 2018 | 1.970B |
| June 30, 2018 | 645.75M |
| March 31, 2018 | 1.056B |
| December 31, 2017 | -481.58M |
| September 30, 2017 | 1.825B |
| June 30, 2017 | -110.11M |
| March 31, 2017 | 1.515B |
| December 31, 2016 | 391.60M |
| September 30, 2016 | 1.161B |
| June 30, 2016 | -698.18M |
| March 31, 2016 | 498.60M |
| December 31, 2015 | -649.11M |
| September 30, 2015 | 994.92M |
| June 30, 2015 | 177.69M |
| March 31, 2015 | 12.14B |
| December 31, 2014 | 1.623B |
| September 30, 2014 | 637.84M |
| June 30, 2014 | 1.188B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
| Merck & Co., Inc. | 5.067B |
| Novo Nordisk A/S | 2.576B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 11.94B |
| Total Expenses (Quarterly) | 9.870B |
| EPS Diluted (Quarterly) | 1.018 |
| Enterprise Value | 128.54B |
| Gross Profit Margin (Quarterly) | 74.46% |
| Profit Margin (Quarterly) | 19.16% |
| Earnings Yield | 5.68% |
| Operating Earnings Yield | 10.82% |
| Normalized Earnings Yield | 9.008 |